Eli Lilly’s Kisunla (donanemab-azbt) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of early symptomatic Alzheimer’s disease. This includes adults with mild cognitive impairment (MCI) and mild dementia stages of the disease. Alzheimer’s disease affects women disproportionately, with nearly two-thirds of Americans diagnosed being women. The pivotal Phase 3 study, TRAILBLAZER-ALZ 2, showed that Kisunla slowed…
A study presented at the recent ESHRE Annual Meeting in Amsterdam has shown that exposure to fine particulate matter (PM) before the retrieval of oocytes during in vitro fertilisation (IVF) can reduce the odds of achieving a live birth by almost 40%. The research, conducted over eight years in Perth, Australia, analyzed 3,659 frozen embryo transfers from 1,836 patients. It found that…
The European Society of Human Reproduction and Embryology (ESHRE) has launched the Female Reproductive Genetics Initiative (FeRGI), a project aimed at translating genetic research in infertility into clinical practice. Developed within the Special Interest Group (SIG) Reproductive Genetics, FeRGI focuses on providing resources and training to clinicians and biologists to improve the diagnosis and treatment of female infertility. Recent advancements over the…
It’s 2024. We still don’t know what causes PCOS. We don’t know how to cure it. And we have a limited understanding how to treat it properly. PCOS stands for Polycystic Ovary Syndrome. It’s a syndrome because we don’t really understand it. It’s a syndrome because in medicine ‘syndrome’ refers to a group or collection of symptoms and signs that consistently occur…
Oxolife, a biotech company specializing in female fertility, has announced promising results from a Phase 2 clinical trial of its non-hormonal fertility pill, OXO-001, at the European Society of Human Reproduction and Embryology (ESHRE) 40th Annual Meeting in Amsterdam. The data indicates that OXO-001 significantly improves embryo implantation, pregnancy, and live birth rates in women undergoing in-vitro fertilization (IVF) and intracytoplasmic sperm…
Every Thursday we send out a curated newsletter on all things femtech and women’s health innovation. This is an excerpt from the latest edition. If you’d like to subscribe, you can do so at the bottom of this page. Highlights Malaica secures $1M pre-seed round to advance maternal healthcare in Sub-Saharan Africa. JOGO Health secures $5.5M in funding, leveraging neuroplasticity to treat chronic pain and incontinence. Mental…
Malaica, a maternal health startup active in Sub-Saharan Africa, has successfully closed a $1M pre-seed funding round. The round was led by Markus Gemuend, former Managing Director of Roche Africa, with participation from Silicon Valley-based Kapor Capital, known for their substantial experience in the maternal health space. Malaica’s approach to maternal health combines personalized care, hybrid models, simplicity, advanced technology, and community…
JOGO Health, a medtech company focused on the treatment of chronic pain and neuromuscular disorders, has closed over $5.5 million in a funding round led by Hourglass Ventures. Due to high demand from investors, JOGO Health is now extending the opportunity to the public through a Regulation CF community investment round on Wefunder. This allows retail investors to participate alongside established firms…
